SCHEMBL321933

SCHEMBL321933

Cc1cc(Br)ccc1C(=O)Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 1/20 0.49
FLT4 P35916 1/20 0.49
KDR P35968 1/20 0.49
MAPT P10636 4/20 0.42
ALDH1A1 P00352 2/20 0.42
DGAT1 O75907 1/20 0.41
UTS2R Q9UKP6 1/20 0.41
CES2 O00748 2/20 0.41
GALR3 O60755 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
CASP1 P29466 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
GPR27 Q9NS67 1/20 0.40
DHODH Q02127 1/20 0.40
MYC P01106 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18431 0.83 ALDH1A1 (0.46) FLT1FLT4KDRMAPTALDH1A1
SCHEMBL29420640 0.81 MAPT (0.49) FLT1FLT4KDRMAPTALDH1A1
SCHEMBL30753064 0.81 KDM4E (0.53) FLT1FLT4KDRMYCNR4A1
SCHEMBL3173571 0.81 FLT1 (0.46) FLT1FLT4KDRMAPTALDH1A1
SCHEMBL117133 0.81 MAPT (0.49) FLT1FLT4KDRMAPTALDH1A1
SCHEMBL6360 0.81 KDM4E (0.53) FLT1FLT4KDRMYCNR4A1
SCHEMBL31173096 0.80 HPGD (0.50) MAPTALDH1A1DGAT1CES2GALR3
Hydrochloric Acid SCHEMBL7676438 0.79 KDM4E (0.52) FLT1FLT4KDRMEN1KMT2A
SCHEMBL428805 0.79 DGAT1 (0.60) FLT1FLT4KDRMAPTDGAT1
SCHEMBL789345 0.79 ALDH1A1 (0.55) FLT1FLT4KDRMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024181097-A1 PHOTOCURABLE COMPOSITION, METHOD FOR PRODUCING CURED ARTICLE, FILM, OPTICAL ELEMENT, IMAGE SENSOR, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, AND RADICAL POLYMERIZATION INITIATOR 富士フイルム株式会社 2024-09-06 WO disclosed
US-20240018121-A1 NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE FOX CHASE CHEMCIAL DIVERSITY CENTER, INC. (US) 2024-01-18 US disclosed
US-20240018121-A1 NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE FOX CHASE CHEMCIAL DIVERSITY CENTER, INC. (US) 2024-01-18 US disclosed
US-20240018121-A1 NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE FOX CHASE CHEMCIAL DIVERSITY CENTER, INC. (US) 2024-01-18 US disclosed
EP-4161904-A1 INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF TOLVAPTAN AND ITS DERIVATIVES Cambrex Profarmaco Milano S.r.l. (IT) 2023-04-12 EP disclosed
WO-2022192162-A1 NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2022-09-15 WO disclosed
WO-2022192162-A1 NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2022-09-15 WO disclosed
WO-2021249877-A1 INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF TOLVAPTAN AND ITS DERIVATIVES CAMBREX PROFARMACO MILANO S.R.L. (IT) 2021-12-16 WO disclosed
EP-2875005-B1 N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF IMPACT THERAPEUTICS INC (CN) 2020-11-11 EP disclosed
US-RE48301-E1 Fused heterocyclic derivatives as S1P modulators ABBVIE B.V. (NL) 2020-11-10 US disclosed
US-6479524-B1 TO PROLONG THE THROMBIN TIME BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-11-12 US disclosed
EP-1149103-A1 THIENYLBENZOYLBENZAZEPINES AS VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2001-10-31 EP disclosed
US-6297234-B1 Arylthiophene vasopressin agonists AMERICAN HOME PRODUCTS CORPORATION 2001-10-02 US disclosed
US-6268360-B1 URINATION DELAY AMERICAN HOME PRODUCTS CORPORATION 2001-07-31 US disclosed
WO-2000046227-A1 THIENYLBENZOYLBENZAZEPINES AS VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-08-10 WO disclosed
US-5891899-A Pharmaceutical xanthene compounds ELI LILLY AND COMPANY LIMITED (GB) 1999-04-06 US disclosed
US-5856503-A ANTICHOLESTEROL AGENTS HOFFMANN-LA ROCHE INC. (US) 1999-01-05 US disclosed
EP-0849263-A2 Pharmaceutical substituted propanoic acid derivatives ELI LILLY AND COMPANY LIMITED (GB) 1998-06-24 EP disclosed
EP-0778271-A2 Aminoalkyl-substituted benzo-heterocyclic compounds F. HOFFMANN-LA ROCHE AG (CH) 1997-06-11 EP disclosed
US-4289781-A Anti-psychotic phthalimidine derivatives ASTRA LAKEMEDEL AKTIEBOLAG (SE) 1981-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018121-A1 NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE ERG28, CYP51A1, MANBA FLT1 4453/4885FLT4 4312/4885KDR 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.